The aim of this study is to examine whether treatment with 75 mg aspirin daily compared with placebo could reduce the risk for a new miscarriage. The treatment starts when the pregnancy is detected on transvaginal ultrasound (around gestational week 6+) and continues to week 35/36. The study is a single center, randomized, placebo-controlled, double blind and stratified for age. 400 participants with the diagnosis idiopathic recurrent abortion are enrolled, 200 in each arm aspirin / placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
400
Live birth
Time frame: delivery
Spontaneous abortion
Time frame: up to 22 weeks
Vaginal bleeding
Time frame: up to 42 weeks
Premature delivery
Time frame: At delivery
intrauterine growth retardation, measured by ultrasound as percentage deviation
Time frame: up to 42 weeks
Preeclampsia
Time frame: up to 42 weeks
Pregnancy induced hypertension
Time frame: up to 42 weeks
Placenta praevia
Time frame: up to 42 weeks
Perinatal mortality
Time frame: Third trimester and 28 days after delivery
Perinatal morbidity
Time frame: 28 days after delivery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.